Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
Tue, September 14, 2010
Mon, September 13, 2010

Micromet to Present at the 2010 UBS Global Life Sciences Conference

BETHESDA, Md.--([ BUSINESS WIRE ])--Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2010 UBS Global Life Sciences Conference, to be held September 20 - 22, 2010 in New York City. Christian Itin, Ph.D., Micrometa™s President and Chief Executive Officer, will present a 30 minute corporate overview on September 20 at 11:30 AM ET.

The presentation will be webcast live and may be accessed by visiting the Micromet website at [ www.micromet.com ]. A replay of the webcast will also be available on the Company's website.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at [ www.micromet.com ].